Development of Visible Spectrophotometric Method and its Validation for Dolutegravir in Tablet Dosage Form

Author:

T. Pawar Vijaykumar1,D. Magadum Mrunalee2

Affiliation:

1. Assistant Professor, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur - 416013 Maharashtra, India.

2. Student, Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Kolhapur - 416013 Maharashtra, India.

Abstract

Objective: There are several methods for analyzing the same, however, they are time-consuming and costly. We created a new spectrophotometric method for determining Dolutegravir (DLT) in tablet dosage forms that is simple, accurate, and precise. We developed and validated a simple, accurate, and precise colorimetric method for the quantitative analysis of Dolutegravir in bulk and dosage form by ICH recommendations in this study. Methodology: There are several methods for analyzing the same, however, they are time-consuming and costly. We created a new spectrophotometric method for determining Dolutegravir (DLT) in tablet dosage forms that is simple, accurate, and precise. In methanol, the initial stock solution of Dolutegravir was prepared. The method is based on the formation of a blue color chromogen complex from Dolutegravir oxidation-reduction with Ferric chloride in the presence of potassium ferricyanide. Result: The color complex was measured at 710nm. Beers law was observedin the concentration range of 3.5-6.5μg/ml witha coefficient of correlation (R2) was 0.998. The system suitability criteria were found to be within the limits. The LOD and LOQ were found to be 0.91 and 2.47, indicating that the method is sensitive. Conclusion: The relative standard deviation (RSD) and percent recovery values were found to be satisfactory, indicating that the proposed method is suitable, accurate, and precise and that it can be used in routine analysis of Dolutegravir in tablet dosage forms, with relatively low-cost solvents.

Publisher

A and V Publications

Reference26 articles.

1. United States Food and Drug Administration, FDA. Approves new drug to treat HIV infection http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm364744.htm [Access Online Aug. 12, 2013].

2. Min S, Song I, Borland J, Chen S, Lou Y, Fujjwara T, Piscitelli SC.Pharmacokinetics and safety of S/GSK1349572, a next-generation HIVintegrase inhibitor, in healthy volunteers. Antimicrob Agents Chemother. 2010; 54(1):254–258. URL:https://doi.org/10.1128/AAC.00842-09.

3. Ribera E, Podzamczer D.Mechanisms of action, pharmacology and interactions of Dolutegravir. Enferm Infecc Microbiol Clin. 2015; 33(1):2–8.URL: https://doi.org/10.1016/s0213-005x(15)30002-1.

4. Mastannama SK, Ananta Sridhar T, Saidulu P. A novel UVspectrophotometric method development and validation of Dolutegravir in bulk and its laboratory synthetic mixture by using 8 M urea as a hydrotropic solubilizing agent. Int J Pharm Sci Drug Res. 2015; 7(4):370–375. URL:http://ijpsdr.com/index.php/ijpsdr/article/view/439.

5. Girija BB, Kiran AB, Ravindra TS, Kakadsachein J, Sanjay Sudhakar P. Development and validation of UV spectrophotometric method for estimation of Dolutegravir sodium in the tablet dosage form. Malaysian J Anal Sci. 2015; 19(6): 1156–1163.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3